|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
cytokine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:affiliatedWith
|
type I interferon
|
|
gptkbp:approvedBy
|
gptkb:FDA
1986
|
|
gptkbp:ATCCode
|
gptkb:L03AB
|
|
gptkbp:brand
|
gptkb:Roferon-A
Intron A
Wellferon
|
|
gptkbp:CASNumber
|
9008-11-1
|
|
gptkbp:category
|
antiviral drug
immunotherapy
antineoplastic agent
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
severe psychiatric disorders
|
|
gptkbp:discoveredBy
|
Isaacs and Lindenmann
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon alfa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits cell proliferation
modulates immune response
induces antiviral proteins
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
19 kDa
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:leukocytes
recombinant DNA technology
|
|
gptkbp:recipient
|
gptkb:interferon_alpha/beta_receptor
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
fatigue
neutropenia
thrombocytopenia
flu-like symptoms
|
|
gptkbp:UNII
|
Q5IXP7R6F7
|
|
gptkbp:usedFor
|
gptkb:chronic_myelogenous_leukemia
gptkb:hairy_cell_leukemia
gptkb:hepatitis_C
gptkb:Kaposi's_sarcoma
gptkb:hepatitis_B
malignant melanoma
|
|
gptkbp:bfsParent
|
gptkb:Ribavirin
gptkb:peginterferon_alfa
|
|
gptkbp:bfsLayer
|
7
|